Table 2.
Changes in LVEF and Interventions With Trastuzumab Therapy
| Continued Trastuzumab Therapy | Temporary Hold of Trastuzumab Therapy | Discontinued Trastuzumab Therapy | Received CV Therapy | |
|---|---|---|---|---|
| Normal LVEF (n=408) | ||||
| Number (%) | 83.8 (n=342) | 6.1 (n=25) | 10.0 (n=41) | 9.8 (n=40) |
| <5% decline in LVEF (%) | 94.4 (n=51) | ‐ | 5.6 (n=3) | 3.7 (n=2) |
| 5–10% decline in LVEF (%) | 92.2 (n=94) | 2.9 (n=3) | 4.9 (n=5) | 5.9 (n=6) |
| ≥10% decline in LVEF (%) | 73.2 (n=131) | 11.2 (n=20) | 15.6 (n=28) | 15.6 (n=28) |
| Low LVEF (n=20) | ||||
| Number (%) | 55.0 (n=11) | 25.0 (n=5) | 20.0 (n=4) | 35.0 (n=7) |
| <5% decline in LVEF (%) | 100.0 (n=2) | ··· | ··· | ··· |
| 5–10% decline in LVEF (%) | ··· | ··· | 100.0 (n=1) | ··· |
| ≥10% decline in LVEF (%) | ··· | 57.1 (n=4) | 42.9 (n=3) | 71.4 (n=5) |
LVEF indicates left ventricular ejection fraction.